Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells
First Claim
1. A method of treating a patient having a disease of or damage to at least one kidney, comprising administering to the patient a homogeneous population of cells obtained from human umbilical cord tissue in an amount effective to treat the disease or damage, wherein the umbilical cord tissue is substantially free of blood, and wherein the population of cells is capable of self-renewal and expansion in culture and has the potential to differentiate;
- does not produce CD31, CD34, CD117 or HLA-DR; and
expresses, relative to a human fibroblast, mesenchymal stem cell, or iliac crest bone marrow cell, increased levels of interleukin 8 and reticulon 1.
8 Assignments
0 Petitions
Accused Products
Abstract
Methods for treating a patient having a disease or damage to at least one kidney are provided. The methods comprise administering cells obtained from human umbilical cord tissue, or administering pharmaceutical compositions comprising such cells or prepared from such cells. When administered, the cells promote and support the repair and regeneration of the diseased or damaged kidney tissue in the patient. Pharmaceutical compositions for use in the inventive methods, as well as kits for practicing the methods are also provided.
-
Citations
14 Claims
-
1. A method of treating a patient having a disease of or damage to at least one kidney, comprising administering to the patient a homogeneous population of cells obtained from human umbilical cord tissue in an amount effective to treat the disease or damage, wherein the umbilical cord tissue is substantially free of blood, and wherein the population of cells is capable of self-renewal and expansion in culture and has the potential to differentiate;
- does not produce CD31, CD34, CD117 or HLA-DR; and
expresses, relative to a human fibroblast, mesenchymal stem cell, or iliac crest bone marrow cell, increased levels of interleukin 8 and reticulon 1. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
- does not produce CD31, CD34, CD117 or HLA-DR; and
-
13. A method of treating a patient having a disease of or damage to at least one kidney, comprising administering to the patient a composition comprising a soluble cell fraction prepared from a homogeneous population of cells obtained from human umbilical cord tissue, wherein the umbilical cord tissue is substantially free of blood, and wherein the population of cells is capable of self-renewal and expansion in culture and has the potential to differentiate;
- does not produce CD31, CD34, CD117 or HLA-DR; and
expresses, relative to a human fibroblast, mesenchymal stem cell, or iliac crest bone marrow cell increased levels of interleukin 8 and reticulon 1.
- does not produce CD31, CD34, CD117 or HLA-DR; and
-
14. A method of treating a patient having a disease of or damage to at least one kidney, comprising administering to the patient a composition comprising a homogeneous population of cells obtained from human umbilical cord tissue and a lysate, extracellular matrix, or conditioned medium prepared from said homogeneous population of cells obtained from human umbilical cord tissue, wherein the umbilical cord tissue is substantially free of blood, and wherein the population of cells is capable of self-renewal and expansion in culture and has the potential to differentiate;
- does not produce CD31, CD34, CD117 or HLA-DR; and
expresses, relative to a human fibroblast, mesenchymal stem cell, or iliac crest bone marrow cell increased levels of interleukin 8 and reticulon 1.
- does not produce CD31, CD34, CD117 or HLA-DR; and
Specification